Blueprint Medicines Co. (NASDAQ:BPMC) CEO Sells $159,407.04 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) CEO Kate Haviland sold 1,446 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the transaction, the chief executive officer now owns 149,378 shares of the company’s stock, valued at $16,467,430.72. This represents a 0.96 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Kate Haviland also recently made the following trade(s):

• On Friday, November 29th, Kate Haviland sold 2,353 shares of Blueprint Medicines stock. The stock was sold at an average price of $96.60, for a total value of $227,299.80.

Blueprint Medicines Stock Performance

NASDAQ:BPMC traded up $4.55 during trading hours on Thursday, reaching $115.63. The company had a trading volume of 1,479,676 shares, compared to its average volume of 990,877. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. Blueprint Medicines Co. has a 1-year low of $72.24 and a 1-year high of $121.90. The business’s 50 day moving average price is $95.28 and its 200-day moving average price is $95.48. The firm has a market cap of $7.35 billion, a PE ratio of -54.80 and a beta of 0.61.

Blueprint Medicines (NASDAQ:BPMC) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.08. The firm had revenue of $128.20 million during the quarter, compared to analysts’ expectations of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The business’s revenue was up 126.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($2.20) EPS. Research analysts forecast that Blueprint Medicines Co. will post -3.67 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently weighed in on BPMC. Stephens restated an “overweight” rating and set a $140.00 target price on shares of Blueprint Medicines in a research note on Thursday, January 2nd. JMP Securities restated a “market outperform” rating and set a $125.00 price objective on shares of Blueprint Medicines in a report on Wednesday, January 15th. JPMorgan Chase & Co. assumed coverage on shares of Blueprint Medicines in a research note on Thursday, November 14th. They issued an “overweight” rating and a $126.00 target price for the company. UBS Group assumed coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They set a “neutral” rating and a $88.00 price target on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $124.00 price objective (down from $135.00) on shares of Blueprint Medicines in a research note on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Blueprint Medicines presently has a consensus rating of “Moderate Buy” and an average price target of $122.72.

Institutional Investors Weigh In On Blueprint Medicines

Several hedge funds have recently modified their holdings of the company. R Squared Ltd acquired a new position in Blueprint Medicines in the 4th quarter worth about $51,000. KBC Group NV increased its position in shares of Blueprint Medicines by 63.9% in the fourth quarter. KBC Group NV now owns 2,625 shares of the biotechnology company’s stock valued at $229,000 after buying an additional 1,023 shares in the last quarter. Fifth Third Bancorp raised its stake in shares of Blueprint Medicines by 207.5% during the 4th quarter. Fifth Third Bancorp now owns 3,075 shares of the biotechnology company’s stock worth $268,000 after buying an additional 2,075 shares during the period. SG Americas Securities LLC lifted its position in shares of Blueprint Medicines by 69.7% during the 4th quarter. SG Americas Securities LLC now owns 4,277 shares of the biotechnology company’s stock valued at $373,000 after buying an additional 1,756 shares in the last quarter. Finally, Empirical Asset Management LLC acquired a new stake in Blueprint Medicines in the 4th quarter valued at $2,348,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.